CV 8102

Drug Profile

CV 8102

Alternative Names: CV-8102

Latest Information Update: 27 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CureVac
  • Class Adjuvants; RNA; RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Rabies

Most Recent Events

  • 05 Jul 2017 Fondazione IRCCS Istituto Nazionale dei Tumori (National Cancer Institute, Naples), Immatics Biotechnologies and CureVac plan a first-in-man phase I/II HepaVac-101 trial for Hepatocellular carcinoma (Combination therapy, Early stage disease) in Belgium, France, Germany, Italy, Spain and United Kingdom (NCT03203005)
  • 27 May 2016 Phase-I development is ongoing in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top